...
首页> 外文期刊>Acta Dermato-Venereologica >A three-year randomized trial in patients with dysplastic naevi treated with oral beta-carotene.
【24h】

A three-year randomized trial in patients with dysplastic naevi treated with oral beta-carotene.

机译:一项为期三年的随机试验,针对接受口服β-胡萝卜素治疗的发育不良性痣患者。

获取原文
获取原文并翻译 | 示例
           

摘要

Ultraviolet irradiation provokes the development of new melanocytic naevi, or changes in existing naevi, leading to repeated surgery of atypical naevi and becoming a continual burden for individuals with many of these lesions. To determine the influence of long-term medication with the radical scavenger beta-carotene on newly developing atypical naevi, a single-centre, randomized, placebo-controlled study, prospective over 3 years, was started double-blind in 62 patients with numerous clinically atypical naevi. Beta-carotene (25 mg) was given twice daily for 36 months in the treatment group (n = 30) and saccharose capsules as placebo in the control group (n = 32). The total number of newly developed naevi in the beta-carotene group (n = 18) was 68 versus 88 in the placebo group (n=21) (not significant). Of 12 different locations on the human body evaluated separately, only in two, the lower arm (p = 0.03) and the feet (p = 0.03), was there a difference for the beta-carotene group in the quantification of naevi. Overall, it is concluded that beta-carotene does not reduce the development of new naevi in patients with numerous atypical naevi.
机译:紫外线照射会引发新的黑素细胞痣的发展或现有痣的改变,从而导致非典型痣的重复手术成为许多这类病变患者的持续负担。为了确定长期服用根治性清除剂β-胡萝卜素对新兴的非典型naevi的影响,一项为期3年的单中心,随机,安慰剂对照研究开始了对62例临床上众多患者的双盲研究。非典型naevi。治疗组(n = 30)每天两次给予β-胡萝卜素(25 mg),持续36个月(n = 30),对照组给予蔗糖胶囊作为安慰剂(n = 32)。 β-胡萝卜素组(n = 18)中新发展的naevi总数为68,而安慰剂组(n = 21)为88(不显着)。在人体的12个不​​同位置中,分别评估了下臂(p = 0.03)和脚(p = 0.03)这两个部位,其中β-胡萝卜素组在naevi定量中存在差异。总的来说,得出的结论是,β-胡萝卜素不会减少患有许多非典型naevi的患者中新naevi的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号